Study #2024-1019
SWOG: Study S2213 a phase III, randomized study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DaraVCD) Induction followed by Autologous Stem Cell Transplant or Dara-VCD consolidation and Daratumumab maintenance in patients with newly diagnosed AL Amyloidosis
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Melody Becnel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-833-670-2212
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.